Finally published underlining the safety of COVID-19 vaccination under immune checkpoint therapy, focusing on a specific adverse event: cytokine release syndrome.
doi.org/10.1038/s43018-022-0…
Great experience working cofirst @SunanjayB and Guy Ungerechts. (1/6)
Aquesta setmana, a l'IDIBAPS...
Thomas Walle s'incorpora a l'#IDIBAPS com a cap del grup "Biomedicina computacional del càncer"
La seva recerca s'ha centrat en el rol de les cèl·luels immunitàries en l'èxit del tractament contra el càncer
👉f.mtr.cool/tbdratetpo
Excited to share a major level-up in my transition to IDIBAPS — and we’re hiring!
We are particularly looking for international PhD candidates to join the DYNAMIS program — with only 2 weeks left to apply.
apply here:
lnkd.in/dTjRxs3Z
1/7
🆕Thomas Walle se incorpora al #IDIBAPS como jefe del grupo "Biomedicina computacional del cáncer"
Su investigación se ha centrado en el rol de las células inmunitarias en el éxito del tratamiento contra el cáncer
👉f.mtr.cool/abqadtnimx
RL20 — Cholangiocarcinoma: Map early systemic immune reprogramming with single-cell multiomics to improve early detection and identify new immunotherapies therapy. with Teresa Macarulla
6/7
This builds on models pioneered by Niels Halama and preserves real tumor architecture and cell–cell interactions, letting us study SASP in a setting far closer to the patient’s tumor than cell culture.
8/9
6/ What does this mean?
Radiotherapy-immune crosstalk is robust but limited
Immune modulation will require targeting sets of chemokines
Dose escalation alone can’t push beyond the biological ceiling
Understanding these concepts is key to better radio-immunotherapies
9/9